A new study suggests that more women are being prescribed beta-3 agonists over anticholinergics for the treatment of overactive bladder (OAB), suggesting that more clinicians may be choosing this ...

Credit: Getty Images. Results are from a meta-analysis of 33 trials involving 35,939 patients with overactive bladder. Overactive bladder treatment using antimuscarinic drugs increases the risks for ...

The FDA has approved mirabegron for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency. The drug, marketed by Astellas Pharma Inc.

A marketing authorization should be given for the medicinal product Obgemsa (vibegron) for treating adults with overactive bladder (OAB) syndrome, the European Medicines Agency (EMA) has said. OAB ...

NEW YORK, June 6 (Reuters) - One of the most common problems in the United States -- an overactive bladder -- is so poorly treated by the current crop of drugs that new medicines have big sales ...

(Reuters) - Watson Pharmaceuticals Inc said it signed a deal to market Antares Pharma Inc's experimental treatment for overactive bladder in the United States and Canada. According to the terms of the ...

Overactive bladder is a long-term condition that won’t go away on its own and may worsen if a person does not get treatment. The condition can be caused by issues in how the brain and bladder ...

It can be annoying if your bladder seems to work overtime and you're headed to the bathroom more often than you'd like, but that doesn't necessarily mean you need medication or that you even have a ...

Active ingredient: Fesoterodine fumarate 4 mg, 8 mg; extended-release tablets. Indication: Overactive bladder (OAB) with urge urinary incontinence, urgency, and frequency. Pharmacology: Fesoterodine ...